Global Plasma Therapy Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Plasma Therapy Market Analysis

The plasma therapy market has witnessed significant growth in recent years due to the rising demand for plasma-derived treatments across various medical conditions. Plasma therapy, which includes treatments such as immune globulin therapy, hemophilia treatment, and wound healing therapies, is gaining popularity because of its ability to utilize the therapeutic proteins present in plasma. The market is driven by an increasing number of patients with chronic diseases, such as autoimmune disorders and bleeding disorders, that benefit from plasma-derived therapies.

Recent advancements in plasma fractionation technology have improved the efficiency and safety of plasma-based treatments. Innovations in protein separation and fractionation processes have led to the development of highly purified products with fewer side effects. The emergence of plasma cell therapy for regenerative medicine and the application of autologous plasma in aesthetic treatments, such as PRP (Platelet-Rich Plasma) injections, have opened up new opportunities.

North America dominates the plasma therapy market due to its advanced healthcare infrastructure, while regions such as Asia-Pacific are experiencing rapid growth driven by increased medical tourism, technological advancements, and rising healthcare investments. The market is expected to expand further as awareness of plasma therapy benefits continues to rise.

Plasma Therapy Market Size

The global plasma therapy market size was valued at USD 436.97 million in 2024 and is projected to reach USD 1217.07 million by 2032, with a CAGR of 13.66 % during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Plasma Therapy Market Trends

“Growing Use of Platelet-Rich Plasma (PRP)”

One significant trend in the plasma therapy market is the growing use of Platelet-Rich Plasma (PRP) for regenerative medicine and aesthetic treatments. This trend is driven by increasing demand for non-invasive therapies that harness the healing properties of autologous plasma to treat various conditions, including joint injuries, hair loss, and skin rejuvenation. For instance, PRP injections have gained widespread popularity for treating conditions such as osteoarthritis and for use in cosmetic dermatology to improve skin texture and reduce wrinkles. Companies such as Regen Lab SA are leading the way in developing and refining PRP technologies that offer effective, low-risk solutions for patients seeking alternatives to traditional surgeries. In addition, advancements in plasma fractionation and protein separation technologies are enhancing the purity and efficacy of plasma-derived products, expanding their applications. This growing interest in regenerative plasma therapies reflects the broader trend toward more personalized and minimally invasive treatments in the healthcare sector, positioning plasma therapy as a key player in the future of medicine.

Report Scope and Plasma Therapy Market Segmentation     

Plasma Therapy Market Definition

Plasma therapy refers to the medical use of plasma, the liquid component of blood, to treat various health conditions. It involves collecting plasma, often from the patient’s own blood (autologous plasma) or from donated plasma (allogenic plasma), and using it for therapeutic purposes.

Plasma Therapy Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, particularly autoimmune disorders and bleeding disorders such as hemophilia, is a significant driver of growth in the plasma therapy market. According to the World Health Organization (WHO), the global incidence of autoimmune diseases is rising, with conditions such as rheumatoid arthritis and systemic lupus erythematosus becoming more common, both of which benefit from plasma-derived therapies such as immune globulin therapy. In addition, the World Federation of Hemophilia (WFH) estimates that approximately 1 in 10,000 people worldwide are affected by hemophilia, a condition that requires frequent plasma-derived clotting factor treatments. These rising cases create a growing demand for plasma-derived therapies to manage and treat chronic conditions, thus driving the market for plasma-based treatments. As the number of patients requiring plasma therapies increases, pharmaceutical companies are focusing on expanding production capabilities, further propelling market growth and ensuring a steady supply of therapeutic plasma.

• Growing Demand for Regenerative Medicine

The growing demand for regenerative medicine is a key driver for the expansion of the plasma therapy market, with Platelet-Rich Plasma (PRP) therapy gaining significant popularity across various medical fields, including orthopedics, dermatology, and cosmetic medicine. PRP is widely used for promoting wound healing, joint injury recovery, hair restoration, and skin rejuvenation. For instance, in orthopedic treatments, PRP injections are used to treat conditions such as osteoarthritis and tendinitis, helping to accelerate tissue healing and reduce inflammation. In dermatology, PRP is increasingly used for hair restoration treatments, especially for conditions such as androgenic alopecia, with studies showing PRP's ability to stimulate hair growth in patients with thinning hair. Similarly, in cosmetic medicine, PRP is used for facial rejuvenation, helping reduce fine lines and improve skin texture. This widespread adoption of PRP in multiple specialties drives the market as more patients and healthcare providers recognize its benefits, fueling the demand for plasma-derived therapies and ensuring continued market growth.

Opportunities

• Increasing Advancements in Plasma Fractionation Technologies

Advancements in plasma fractionation technologies present a significant market opportunity for the plasma therapy market, as technological improvements in plasma fractionation and protein separation processes have greatly enhanced the purity, safety, and effectiveness of plasma-derived products. For instance, newer techniques such as high-throughput chromatography and affinity purification enable the more efficient separation of valuable proteins such as immunoglobulins and clotting factors, which are essential for treating conditions such as hemophilia and immune deficiencies. These advancements ensure that the final products are of higher quality with fewer impurities, leading to reduced risk of adverse reactions and increased patient safety. As a result, demand for plasma-derived therapies, such as immune globulin therapy and albumin, is rising globally. This progress opens up new opportunities for pharmaceutical companies to develop more effective and widely used treatments, especially in areas such as autoimmune disorders, hemophilia, and regenerative medicine, which further drives market growth.

• Rising Medical Tourism

Rising medical tourism presents a significant market opportunity for the plasma therapy market, as more patients from around the world seek affordable and effective plasma-derived treatments in regions such as Asia-Pacific. Countries such as India, Thailand, and Malaysia have become key destinations for medical tourism due to their well-established healthcare infrastructure, cost-effective treatments, and skilled medical professionals. For instance, India has seen a rise in patients traveling for treatments such as Platelet-Rich Plasma (PRP) therapy for joint injuries and hair restoration, as well as immune globulin therapies for immune deficiencies. The affordability of these treatments in comparison to Western countries, along with the availability of advanced plasma fractionation technologies, makes medical tourism a growing trend. As patients increasingly turn to these countries for their medical needs, the demand for high-quality plasma therapies rises, creating a significant opportunity for healthcare providers and pharmaceutical companies to tap into this expanding market.

Restraints/Challenges

• High Treatment Costs

High treatment costs in the plasma therapy market stem from the resource-intensive nature of plasma collection, processing, and distribution, which require significant investments in infrastructure, technology, and logistics. For instance, collecting plasma from donors involves strict adherence to safety protocols, including screening and testing to ensure the quality and safety of the plasma, all of which contribute to higher operational costs. Furthermore, fluctuations in donor availability can disrupt supply, as donor turnout may vary seasonally or due to external factors such as the COVID-19 pandemic, which resulted in a notable reduction in donations. Regulatory hurdles, including the need for compliance with complex global safety standards, add another layer of complexity and cost to the process. For instance, manufacturers must navigate diverse regulations across regions, which can delay production and distribution. These combined factors create a highly sensitive market, where disruptions in plasma supply can lead to increased prices and limited availability of plasma-derived therapeutics, impacting both market stability and patient access. This issue highlights the challenge of balancing cost efficiency with ensuring a steady and secure supply of plasma for therapeutic use.

• Stringent Regulatory Frameworks

Stringent regulatory frameworks play a pivotal role in ensuring the safety and efficacy of plasma therapies, but they also present significant challenges for the global plasma therapy market. Regulatory agencies, such as the U.S. FDA and the European Medicines Agency (EMA), enforce rigorous guidelines on plasma collection, manufacturing, and distribution, ensuring that products meet high standards for patient safety. For instance, plasma donation centers must comply with detailed protocols that include donor screening, testing for infections, and ensuring the safe processing of plasma, all of which incur substantial costs. In addition, the complexity of the plasma protein production process requiring advanced technologies and facilities—further drives up the cost of plasma-based therapeutics. These high production costs translate into elevated treatment prices, making it difficult for patients, particularly in low-income regions, to access these life-saving therapies. For instance, therapies derived from plasma proteins, such as immunoglobulins and clotting factors, are crucial for patients with conditions such as hemophilia or immunodeficiencies, yet the prohibitive cost often leads to limited access, exacerbating health disparities. As a result, while regulatory standards are essential for patient safety, they also contribute to the higher pricing and reduced accessibility of plasma therapies, presenting a major market challenge.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Plasma Therapy Market Scope

The market is segmented on the basis of type, source, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Pure PRP
• Leucocyte-Rich PRP
• Pure Platelet-Rich Fibrin
• Leukocyte-Rich Fibrin

Source

• Autologous
• Allogenic

Application

• Orthopedics
  • Arthritis
  • Chronic Tendinitis
  • Bone Repair & Regeneration
• Dermatology
  • Androgenic Alopecia
  • Plastic Surgery
• Dental
• Cardiac Muscle Injury
• Nerve Injury
• Others

End User

• Hospitals and Clinics
• Research Institutions

Plasma Therapy Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, source, application, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the plasma therapy market, driven by the growing number of hospitals and clinics that offer plasma-based treatments. The region benefits from heightened awareness among blood donors, which increases the availability of plasma for therapeutic use. In addition, advanced protein fractionation processes, which enhance the quality and efficiency of plasma-derived therapies, are widely implemented in the region. These factors, combined with ongoing investments in healthcare infrastructure, are expected to accelerate the growth of the plasma therapy market in North America throughout the forecast period.

Asia-Pacific is expected to experience highest growth in the plasma therapy market, fueled by the increasing influx of medical tourism in the region. As more patients from around the world seek advanced treatments, the demand for high-quality plasma therapies is rising. In addition, rapid technological advancements in plasma collection, fractionation, and storage are enhancing the efficiency and accessibility of treatments. With healthcare infrastructure improving and rising awareness about plasma-based therapies, the region is poised for significant market expansion during the forecast period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Plasma Therapy Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Plasma Therapy Market Leaders Operating in the Market Are:

• Arthrex, Inc. (U.S.)
• Bio Products Laboratory Ltd. (U.K.)
• Takeda Pharmaceutical Company Limited (Japan)
• Biotest AG (Germany)
• Cambryn Biologics (U.S.)
• China Biologic Products Holdings, Inc. (China)
• CSL (Australia)
• Medical Device Business Services, Inc. (U.S.)
• Grifols, S.A. (Spain)
• Kedrion S.p.A. (Italy)
• Octapharma AG (Switzerland)
• Regen Lab SA (Switzerland)
• Stryker (U.S.)
• Telecris (Spain)
• Baxter (U.S.)
• Sanquin Ltd. (Netherlands)
• LFB (France)
• TERUMO BCT, INC. (Japan)

Latest Developments in Plasma Therapy Market

• In October 2021, BioLife Plasma Services (U.S.) launched a new plasma center in Worcester, to address the rising demand for plasma-based therapies
• In August 2021, Biotest AG (Germany) opened its sixth plasma collection center in the Czech Republic, ensuring a long-term supply of plasma for therapeutic needs
• In July 2020, Grifols, a prominent producer of plasma-derived medicines, signed an agreement with GC Pharma to acquire a plasma fractionation facility in Montreal, along with 11 U.S.-based plasma collection centers and two purification facilities, strengthening its market position and revenue
• In June 2020, CSL Behring (Australia) reached an agreement to acquire Vitaeris Inc., a clinical-stage biotechnology company, to advance the Phase III development of canakinumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB)
• In March 2020, Takeda Pharmaceutical Company Limited initiated the development of anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)-TAK-888 for COVID-19 treatment, accelerating therapeutic advancements for effective disease management

SKU-14345